How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Is the proposed process for updating TA924 appropriate to achieve useful and usable guidance?

  • Question on Consultation

    Is the proposed process sufficiently clear? Are further details of the proposed process required by stakeholders?

  • Question on Consultation

    Should NICE consider adapting other elements of the proposed process to achieve more useful and usable guidance?

  • Question on Consultation

    Do you have any other comments on the proposed process for updating TA924 within the proportionate decision-making process?

  • Question on Consultation

    Would it be challenging to implement of any of the recommendations for the updated TA? Please say why and for whom, and how these could be mitigated.

  • Question on Consultation

    Would implementation of any of the recommendations have significant cost implications?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Review proposal of TA924

Closed for comments This consultation ended on at   Request commenting lead permission

Summary of TA considered for review

A summary of the TA considered for review is listed in Table 1.

Table 1: TAs to be considered for review

TA number

Title

Recommendation

Year of publication

TA924

Tirzepatide for treating type 2 diabetes

Tirzepatide is recommended for treating type 2 diabetes alongside diet and exercise in adults when it is insufficiently controlled only if:

  • triple therapy with metformin and 2 other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and

  • they have a body mass index (BMI) of 35 kg/m2 or more, and specific psychological or other medical problems associated with obesity, or

  • they have a BMI of less than 35 kg/m2, and:

    • insulin therapy would have significant occupational implications, or

    • weight loss would benefit other significant obesity-related complications.

Use lower BMI thresholds (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

2025